Autologous bone marrow transplantation followed by involved Field radiotherapy in patients with relapsed or refractory hodgkin's disease

Jill A. Moormeier*, Stephanie F. Williams, Lynne S. Kaminer, Erin D. Ellis, Miriam Garner, Ramez Farah, Ralph R. Weichselbaum, Jacob D. Bitran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Twenty-six patients with refractory or relapsed Hodgkin's disease were treated with high dose cyclophosphamide, BCNU, etoposide, and thiotepa followed by autologous hematopoietic stem cell rescue. Involved field radiotherapy was given following hematologic recovery in selected patients. The overall response rate to the high dose chemotherapy was 69% with 34% complete responses. Following radiotherapy, the complete response rate increased to 50%. The predicted disease-free survival at two years is 22%. Toxicity with this regimen was significant, with five patients dying as a result of transplant related complications. We conclude that the addition of thiotepa to the standard CBV regimen did not result in improved therapeutic efficacy and possibly contributed significantly to the toxicity of the treatment.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalLeukemia and Lymphoma
Volume5
Issue number4
DOIs
StatePublished - 1991
Externally publishedYes

Keywords

  • Autologous bone marrow transplantation
  • Hodgkin's disease
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Autologous bone marrow transplantation followed by involved Field radiotherapy in patients with relapsed or refractory hodgkin's disease'. Together they form a unique fingerprint.

Cite this